Neuphoria Therapeutics Inc (NEUP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) has a cash flow conversion efficiency ratio of -0.217x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.44 Million) by net assets ($29.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NEUP net asset quality score to measure how much of total assets are equity-financed.
Neuphoria Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NEUP operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Neuphoria Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuphoria Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YSX Tech. Co., Ltd Class A Ordinary Shares
NASDAQ:YSXT
|
-0.250x |
|
Efficient E Solutions Bhd
KLSE:0064
|
-0.011x |
|
Getabec Public Company Limited
BK:GTB
|
-0.045x |
|
VRX Silica Ltd
AU:VRX
|
-0.090x |
|
STS Group AG
XETRA:SF3
|
0.115x |
|
CrystalGenomics Inc
KQ:083790
|
-0.129x |
|
Spacenet Enterprises India Limited
NSE:SPCENET
|
0.036x |
|
ClearSign Combustion Corporation
NASDAQ:CLIR
|
-0.135x |
Annual Cash Flow Conversion Efficiency for Neuphoria Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Neuphoria Therapeutics Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see NEUP market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $28.87 Million | $77.23 Million | 2.675x | +418.66% |
| 2024-06-30 | $17.49 Million | $-14.68 Million | -0.839x | -24.91% |
| 2023-06-30 | $14.65 Million | $-9.85 Million | -0.672x | -75.80% |
| 2022-06-30 | $39.15 Million | $-14.97 Million | -0.382x | -141.35% |
| 2021-06-30 | $35.76 Million | $-5.66 Million | -0.158x | +48.54% |
| 2020-06-30 | $8.71 Million | $-2.68 Million | -0.308x | +65.04% |
| 2019-06-30 | $12.39 Million | $-10.91 Million | -0.880x | +27.00% |
| 2018-06-30 | $12.46 Million | $-15.02 Million | -1.206x | -2503.99% |
| 2017-06-30 | $31.09 Million | $-1.44 Million | -0.046x | +90.44% |
| 2016-06-30 | $31.69 Million | $-15.36 Million | -0.485x | -340.76% |
| 2015-06-30 | $24.52 Million | $4.94 Million | 0.201x | +165.79% |
| 2014-06-30 | $42.20 Million | $-12.91 Million | -0.306x | -15.06% |
| 2013-06-30 | $37.79 Million | $-10.05 Million | -0.266x | -75.62% |
| 2012-06-30 | $26.51 Million | $-4.01 Million | -0.151x | +48.27% |
| 2011-06-30 | $30.67 Million | $-8.98 Million | -0.293x | +10.76% |
| 2010-06-30 | $21.64 Million | $-7.10 Million | -0.328x | +0.74% |
| 2009-06-30 | $15.09 Million | $-4.99 Million | -0.330x | -2.93% |
| 2008-06-30 | $20.60 Million | $-6.61 Million | -0.321x | +1.91% |
| 2007-06-30 | $19.25 Million | $-6.30 Million | -0.327x | +29.10% |
| 2006-06-30 | $8.12 Million | $-3.75 Million | -0.462x | -12.78% |
| 2005-06-30 | $8.14 Million | $-3.33 Million | -0.409x | +14.34% |
| 2004-06-30 | $6.24 Million | $-2.98 Million | -0.478x | +13.99% |
| 2003-06-30 | $4.52 Million | $-2.51 Million | -0.556x | -7.28% |
| 2002-06-30 | $5.62 Million | $-2.91 Million | -0.518x | -3.23% |
| 2001-06-30 | $5.20 Million | $-2.61 Million | -0.502x | -79.68% |
| 2000-06-30 | $3.02 Million | $-843.87K | -0.279x | -196.31% |
| 1999-06-30 | $-363.81K | $-105.47K | 0.290x | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more